Key result
MRAs reduce office SBP by ~9 mmHg vs control in resistant hypertension.
Why the study?
The comparative effect of different treatments on resistant hypertension was not comprehensively established.
Do different pharmacological, device-based, and lifestyle interventions reduce blood pressure in patients with resistant hypertension?
Meta-Analysis
Do different pharmacological, device-based, and lifestyle interventions reduce blood pressure in patients with resistant hypertension?
In a network meta-analysis, MRA emerged as the most effective priority treatment for resistant hypertension, with aldosterone synthase inhibitors and renal denervation as optimal alternatives.
Answers are grounded in this paper and cite their sources.
Network meta-analysis ranks RH regimens by BP effect; leaves open optimal selection pending direct trials.
PURPOSE: Our study tends to perform a network meta-analysis to compare the effect of different treatments on resistant hypertension (RH). METHODS: A systematic search was conducted in databases up to April 1, 2026. We conducted a network meta-analysis using random effects to compare the change of systolic/diastolic blood pressure (SBP/DBP) between the following interventions: second-generation renal denervation (RDN), mineralocorticoid receptor antagonist (MRA), endothelin receptor antagonist, aldosterone synthase inhibitor (ASI), sodium-glucose cotransporter-2 inhibitors, baroreflex activation therapy, central arteriovenous anastomosis, lifestyle, and control group. RESULTS: Thirty-three eligible studies were included in the final analysis. After conducting sensitivity analyses, MRA significantly lowered both office and 24-h blood pressure (BP) compared to control group (mean difference -9.11, [95% confidence interval -10.44 to -7.79] for office SBP; -4.97 [-5.83 to -4.11] for office DBP; -9.64 [-11.73 to -7.54] for 24-h SBP; -3.75 [-5.08 to -2.42] for 24-h DBP). RDN effectively reduced both office and 24-h BP, and it caused a large reduction in office DBP compared to control group (-6.63 [-8.58 to -4.68] for office DBP; -3.36 [-4.57 to -2.14] for 24-h DBP). Lifestyle and ASI effectively reduced office and 24-h BP, and it as well as MRA were almost in the top three treatments. CONCLUSION: MRA can be the priority treatment for RH. ASI and RDN are also optimal alternatives to MRA, particularly suitable for 24-h BP and uncontrolled DBP management, respectively. A combination of lifestyle alongside pharmacological/device-based therapies may represent the optimal approach. More trials concerning other treatments for RH are needed.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) conducted a meta-analysis in resistant hypertension (RH). Mineralocorticoid receptor antagonist (MRA) vs. Control group was evaluated on change of office systolic blood pressure (SBP) (MD -9.11, 95% CI -10.44 to -7.79). Mineralocorticoid receptor antagonists lowered office systolic blood pressure compared to control in patients with resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: